News

Designed to discretely and continuously measure glucose levels through a sensor in the back of the upper arm or abdomen, Abbott’s FreeStyle Navigator system is said ti provide

Mr Pickering will also be elected to the company’s board of directors. In conjunction with Mr Pickering’s appointment, the corporate headquarters will now be located within the company’s

The US Phase III study will enroll 306 new-onset type 1 diabetes patients, who are within three months of diagnosis. In one arm of the study, 102 patients

As a part of agreement, Exelixis will continue to be responsible for the Phase I clinical trial until the point that a maximum tolerated dose (MTD) is determined.

Results show that GA 40mg was safe and well-tolerated in ALS patients, however, the study’s primary and secondary endpoints were not met. The study was designed to assess

When delivered topically to the wound, nitric oxide gas (gNO) has a number of known activities believed to be beneficial in the healing of wounds, including antimicrobial and

Timothy Noyes, president and CEO of Proteon, said: “The issuance of this patent further strengthens and broadens Proteon’s elastase vasodilation franchise. With this patent in hand, Proteon Therapeutics

The Advance trial will enroll 1,050 treatment-naive genotype 1 hepatitis C virus (HCV) patients and will evaluate two 24-week telaprevir-based regimens in comparison to a 48-week control arm.

Plicera was generally well-tolerated at all doses evaluated, and no serious adverse events were reported. Glucocerebrosidase (GCase) activity as measured in white blood cells was increased in 20